Teva's Copaxone fails to show greater efficacy at higher dose
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries' Copaxone (glatiramer acetate) has failed to show increased efficacy at a 40mg dose, compared with the licensed 20mg dose, in a Phase III study in relapsing-remitting multiple sclerosis that was looking at reducing the relapse rate.